LAX.SH
MEDPLUS HEALTH SERV LTD·PHARMACEUTICALS 72.79·Retailing Companies
Price
814.7
-0.19%52W Range
Market Cap
₹9,787.57 Cr
Traded: ₹10.65 Cr (0.11%) 0.0x
Free Float: ₹1,458.35 Cr (0.73% of FF traded)
Volume · 60D trend
1.31 L 0.0x
Delivery: % 0.0x
View Delivery Data
Returns
Valuation
Business Strength
Growth (3Y CAGR)
Balance Sheet
Cash Position
Others
MTF Exposure Trend
60 sessions · funded amount, % of FF, daily delta
LAX.SH
Growth Trends
| Metric | 10Y | 5Y | 3Y | 1Y | TTM | Trend |
|---|---|---|---|---|---|---|
| ROE | +8.0% | +8.0% | +8.0% | -- | -- | Stable |
| Sales | +15.0% | +18.0% | +15.0% | -- | +12.0% | Decelerating |
| Profit | +37.0% | +29.0% | +67.0% | -- | +50.0% | Stable |
| Return | -- | -- | +12.0% | +7.0% | -- | Decelerating |
Quarterly Results
Mar 2026
21 MayDec 2025
30 JanSep 2025
Jun 2025
Mar 2025
Dec 2024
Sep 2024
Jun 2024
Mar 2024
Dec 2023
Sep 2023
Jun 2023
Mar 2023
Dec 2022
Revenue & Margin Trends
Annual
Quarterly
Balance Sheet Health
Leverage
Efficiency
Cash Position
Detailed Financials
Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 | Jun 2023 | Mar 2023 | Dec 2022 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 1,864 | 1,806 | 1,679 | 1,543 | 1,510 | 1,561 | 1,576 | 1,489 | 1,490 | 1,441 | 1,409 | 1,284 | 1,253 | 1,190 |
| Expenses | 1,695 | 1,648 | 1,530 | 1,412 | 1,373 | 1,429 | 1,452 | 1,395 | 1,385 | 1,350 | 1,324 | 1,213 | 1,171 | 1,119 |
| Operating Profit | 169 | 159 | 149 | 131 | 136 | 133 | 124 | 94 | 106 | 92 | 85 | 71 | 82 | 72 |
| OPM % | 9.0% | 9.0% | 9.0% | 8.0% | 9.0% | 8.0% | 8.0% | 6.0% | 7.0% | 6.0% | 6.0% | 6.0% | 7.0% | 6.0% |
| Other Income | 21 | 18 | 17 | 15 | 16 | 13 | 12 | 9 | 10 | 10 | 10 | 9 | 14 | 11 |
| Interest | 33 | 31 | 29 | 27 | 27 | 26 | 25 | 25 | 25 | 24 | 24 | 23 | 22 | 21 |
| Depreciation | 76 | 73 | 69 | 66 | 64 | 62 | 63 | 60 | 59 | 57 | 55 | 52 | 56 | 46 |
| Profit Before Tax | 80 | 73 | 69 | 53 | 61 | 57 | 48 | 18 | 32 | 20 | 16 | 5 | 17 | 16 |
| Tax % | 20.0% | 21.0% | 19.0% | 20.0% | 16.0% | 19.0% | 19.0% | 19.0% | -5.0% | 31.0% | 12.0% | 26.0% | -54.0% | 17.0% |
| Net Profit | 64 | 58 | 56 | 42 | 51 | 46 | 39 | 14 | 34 | 14 | 15 | 4 | 27 | 13 |
| Exceptional Items | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- |
| EPS (Rs) | 5.3 | 4.8 | 4.6 | 3.5 | 4.3 | 3.8 | 3.2 | 1.2 | 2.8 | 1.1 | 1.2 | 0.3 | 2.2 | 1.1 |
| Sales Growth (YoY) | 23.4% | 15.7% | 6.5% | 3.6% | 1.3% | 8.3% | 11.8% | 16.0% | 18.9% | 21.1% | -- | -- | -- | -- |
| Sales Growth (QoQ) | 3.2% | 7.6% | 8.8% | 2.2% | -3.3% | -0.9% | 5.8% | -0.1% | 3.4% | 2.3% | 9.7% | 2.5% | 5.3% | -- |
| OP Growth (YoY) | 24.3% | 19.5% | 20.2% | 39.4% | 28.3% | 44.6% | 45.9% | 32.4% | 29.3% | 27.8% | -- | -- | -- | -- |
| OP Growth (QoQ) | 6.3% | 6.7% | 13.7% | -3.7% | 2.3% | 7.3% | 31.9% | -11.3% | 15.2% | 8.2% | 19.7% | -13.4% | 13.9% | -- |
| Profit Growth (YoY) | 25.0% | 26.0% | 43.0% | 195.0% | 54.0% | 234.0% | 166.0% | 279.0% | 26.0% | 2.0% | 122.0% | 18.0% | 127.0% | -22.0% |
| EPS Growth (YoY) | 24.2% | 25.9% | 42.9% | 195.0% | 53.8% | 233.0% | 165.6% | 275.0% | 25.1% | 2.7% | -- | -- | -- | -- |
| EPS Growth (QoQ) | 10.6% | 4.1% | 30.8% | -17.5% | 12.0% | 18.2% | 170.0% | -57.0% | 142.6% | -5.7% | 281.3% | -85.7% | 99.1% | -- |
| OP Margin | 9.1% | 8.8% | 8.9% | 8.5% | 9.0% | 8.5% | 7.9% | 6.3% | 7.1% | 6.4% | 6.0% | 5.5% | 6.5% | 6.0% |
| Net Margin | 3.4% | 3.2% | 3.3% | 2.7% | 3.4% | 3.0% | 2.5% | 0.9% | 2.3% | 1.0% | 1.1% | 0.3% | 2.1% | 1.1% |
| Material Cost % | 74.0% | 74.0% | 74.0% | 74.0% | 73.0% | 75.0% | 76.0% | 78.0% | 77.0% | 78.0% | 78.0% | 79.0% | 77.0% | 78.0% |
| Employee Cost % | 13.0% | 13.0% | 13.0% | 13.0% | 13.0% | 12.0% | 11.0% | 11.0% | 11.0% | 11.0% | 11.0% | 11.0% | 12.0% | 12.0% |
| P/S | 1.42 | 1.67 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- |
| P/E | 44.47 | 52.71 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- |
| P/B | 4.96 | 5.93 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- |
Exchange Filings
50Medplus Health Services Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 21/07/2026 ,inter alia, to consider and approve the un-audited Standalone ....
Update under Regulation 30 read with Para A Part A of Schedule III of SEBI (Listing Obligations and Disclosure Requirements) Regulations,2015
Update under Regulation 30 read with Para A Part A Schedule III of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015
Compliance Certificate under Reg. 74(5) of SEBI (DP) Regulations, 2018
Update under Regulation 30 read with Para A Part A of Schedule III of SEBI ( Listing Obligation and Disclosure Requirements ) Regulations, 2015
Update under Regulation 30 read with Para A Part A of Schedule III of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015
Update under Regulation 30 read with Para A Part A of Schedule III of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015
Update under Regulation 30 read with Para A Part A of Schedule III of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015
Intimation of Trading Window Closure under SEBI (Prohibition of Insider Trading) Regulation, 2015
Update under Regulation 30 read with Para A Part A of Schedule III of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015
Update under Regulation 30 read with Para A Part A of Schedule III of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015
Update under Regulation 30 read with Para A part A of Schedule III of SEBI (Listing Obligations and Disclosure Requirements), Regulations ,2015
Update under Regulation 30 read with Para A Part A of Schedule III of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015
Intimation under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations,2015 regarding completion of tenure of Mr.Madhavan Ganesan (DIN: 01674529) and Mr.Murali ....
Update under Regulation 30 read with Para A Part A of Schedule III of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015
Update under Regulation 30 read with Para A Part A of Schedule III of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015
Update under Regulation 30 read with Para A Part A of Schedule III of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015
Update under Regulation 30 read with Para A Part A of Schedule III of SEBI (Listing Obligations and Disclosure Requirements) REgulations, 2015
Submission of Annual Secretarial Compliance Report for the financials year ended March 31, 2026
Submission of Transcript of Earnings Call
Update under Regulation 30 read with Para A Part A of Schedule III of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015
Submission of Newspaper Clippings
Update under Regulation 30 read with Para A Part A of Schedule III of SEBI (Listing Obligations and Dicsloure Requirements) Regulations, 2015
Intimation of Schedule of Analyst / Institutional Investor Meeting
Submission of Audio Recordings of Earnings Call
Outcome of Board Meeting held on May 20, 2026 as per SEBI (LODR) Regulations, 2015
Allotment of Equity shares under MedPlus ESOP Scheme 2021
Financial Results for the quarter and year ended on March 31, 2026
Presentation of Earings Call with Analysts / Institutional Investors on Audited Financial Results
Update under Regulation 30 read with Para A Part A of Schedule III of SEBI (Listing Obligations and Discloure Requirements) Regulations, 2015
Update under Regulation 30 read with Para A Part A of Schedule III of SEBI (Listing Obligations and Discloure Requirements) Regulations, 2015
Update under Regulation 30 read with Para A Part A of Schedule III of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015
Update under Regulation 30 read with Para A Part A of Schedule III of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015
Schedule of Analysts or Institutional Investors Meet - Earnings Call with respect to audited Financial Results of the Company for the quarter and financial year ended March 31, 2026
Update under Regulation 30 read with Para A Part A of Schedule III of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015
Update under Regulation 30 read with Para A Part A of Schedule III of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015
Update under Regulation 30 read with Para A Part A of Schedule III of SEBI (Listing Obliations and Disclosure Requirements) Regulations, 2015
Update under Regulation 30 read with Para A Part A of Schedule III of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015
The Board Meeting to be held on 29/05/2026 has been revised to 20/05/2026 The Board Meeting to be held on 29/05/2026 has been revised to 20/05/2026 to consider and approve the audited Standalone ....
Update under Regulation 30 read with Para A Part A of Schedule III of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015
Update under Regulation 30 read with Para A Part A of Schedule III of SEBI (Listing Obligations and Disclosure REquirements) Regulations, 2015.
Update under Regulation 30 read with Para A of Part A of Schedule III of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015
Update under Regulation 30 read with Para A Part A of Schedule III of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015
Update under Regulation 30 read with Para A Part A of Schedule III of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015
Update under Regulation 30 read with Para A Part A of Schedule III of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015
Update under Regulation 30 read with Para A Part A of schedule III of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015
Update under Regulation 30 read with Para A Part A of Schedule III of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015
Certificate under Regulation 74(5) of SEBI (DP) Regulations, 2018
Update under Regulation 30 read with Para A Part A of Schedule III of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015
Update under Regulation 30 read with Para A Part A of Schedule III of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015
Concalls
20Feb 2026
28 Feb 2026Nov 2025
30 Nov 2025Aug 2025
31 Aug 2025May 2025
31 May 2025Feb 2025
28 Feb 2025Nov 2024
30 Nov 2024Aug 2024
31 Aug 2024May 2024
31 May 2024Feb 2024
29 Feb 2024Feb 2024
29 Feb 2024Nov 2023
30 Nov 2023Aug 2023
31 Aug 2023May 2023
31 May 2023Feb 2023
28 Feb 2023Feb 2023
28 Feb 2023Feb 2023
28 Feb 2023Nov 2022
30 Nov 2022Aug 2022
31 Aug 2022Jun 2022
30 Jun 2022Feb 2022
28 Feb 2022Held by ETFs
3 ETFs hold MEDPLUS · sorted by weight
Held by Mutual Funds
2 schemes hold MEDPLUS · sorted by weight